MD Anderson Cancer Center (101)

Houston, Texas 77030

0 studies enrolling now · 3 studies all time

What they study most

AML With Monocytic Differentiation, CMML, Solid Tumor, Adult

Studies at this site

• IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML — Completed
• First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors — Completed
• Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors — Completed